Ardelyx, Inc. (NASDAQ:ARDX – Get Free Report) insider Joseph James Reilly sold 3,982 shares of the stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $3.86, for a total transaction of $15,370.52. Following the transaction, the insider owned 145,854 shares of the company’s stock, valued at approximately $562,996.44. The trade was a 2.66% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Ardelyx Stock Performance
ARDX stock traded up $0.04 during mid-day trading on Tuesday, hitting $3.78. The company had a trading volume of 3,418,138 shares, compared to its average volume of 5,069,888. The company has a debt-to-equity ratio of 1.69, a quick ratio of 3.15 and a current ratio of 3.34. The firm has a market cap of $941.94 million, a PE ratio of -17.18 and a beta of 0.70. Ardelyx, Inc. has a 12 month low of $3.72 and a 12 month high of $8.40. The stock’s fifty day moving average price is $4.97 and its two-hundred day moving average price is $5.75.
Ardelyx (NASDAQ:ARDX – Get Free Report) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). Ardelyx had a negative net margin of 12.35% and a negative return on equity of 36.00%. The company had revenue of $120.88 million for the quarter, compared to the consensus estimate of $121.03 million. During the same period in the prior year, the company earned ($0.08) earnings per share. The firm’s revenue was up 34.3% on a year-over-year basis. On average, analysts forecast that Ardelyx, Inc. will post -0.2 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Check Out Our Latest Analysis on ARDX
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Ardelyx during the 2nd quarter worth approximately $35,000. SCS Capital Management LLC purchased a new position in Ardelyx during the second quarter valued at $52,000. ADAR1 Capital Management LLC bought a new stake in Ardelyx during the second quarter valued at about $56,000. State of Wyoming bought a new position in shares of Ardelyx in the second quarter worth about $61,000. Finally, PVG Asset Management Corp purchased a new position in shares of Ardelyx during the 1st quarter valued at about $65,000. 58.92% of the stock is currently owned by institutional investors.
Ardelyx Company Profile
Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.
Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.
Read More
- Five stocks we like better than Ardelyx
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Receive News & Ratings for Ardelyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx and related companies with MarketBeat.com's FREE daily email newsletter.
